At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Deferiprone DR tablets 1000 mg (Low dosage) +1 moredrug
Likely dose
Deferiprone DR tablets 1000 mg (Low dosage)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
In Brief
A Phase 2 clinical trial evaluating Deferiprone DR tablets 1000 mg (Low dosage) and Deferiprone DR tablets 1000 mg (High dosage) for Iron Overload Due to Repeated Red Blood Cell Transfusions. Completed, enrolled 30 participants across 5 sites in 4 countries.
Detailed Summary
Safety, tolerability, and acceptability of twice-daily dosing with deferiprone delayed-release (DR) tablets in patients with systemic iron overload.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Greece, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartMar 2019
Primary CompletionDec 2019
Study CompletionDec 2019
TodayJul 2026
First PostedJan 14, 2019
Enrollment StartMar 6, 2019
Primary CompletionDec 4, 2019
Study CompletionDec 19, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.5 years ago
Interventions
Deferiprone DR tablets 1000 mg (Low dosage)drug
Deferiprone DR tablets 1000 mg
Deferiprone DR tablets 1000 mg (High dosage)drug
Deferiprone DR tablets 1000 mg